Kevin Eisenfrats

Kevin co-founded Contraline and has been CEO since its inception. Kevin has a research background in immunotherapy and in vitro fertilization. At Contraline, Kevin provides vision, leads fundraising, and business development. He is an inventor on 20+ patents relating to novel contraceptive drugs and devices. In 2017, Kevin was named on the Forbes "30 Under 30" in Healthcare. He has a degree in Nanomedicine Engineering from the University of Virginia.